Study shows game-changing obesity drug more than halves risk of type 2 diabetes
The risk of type 2 diabetes (T2D) is more than halved by weekly injections of new obesity drug semaglutide, according to new research being presented at the annual […]
The risk of type 2 diabetes (T2D) is more than halved by weekly injections of new obesity drug semaglutide, according to new research being presented at the annual […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.